NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics' Sapu003 Presentation at 2025 San Antonio Breast Cancer Symposium
TL;DR
Oncotelic's Sapu003 presentation at the 2025 breast cancer symposium positions the company ahead in developing advanced cancer therapies with improved efficacy.
Sapu003 is a novel Deciparticle formulation of everolimus designed to enhance bioavailability, reduce toxicity, and improve tumor penetration through nanomedicine technology.
This advanced cancer therapy development promises better treatment outcomes for patients with metastatic breast cancer and other cancers, improving quality of life.
Oncotelic's innovative nanomedicine platform transforms cancer treatment by using Deciparticle technology to deliver drugs more effectively to tumors.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics announced that Sapu003, an investigational intravenous Deciparticle everolimus developed by Sapu Nano, has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium.
Sapu003 is a novel Deciparticle formulation of everolimus designed to improve bioavailability, reduce toxicity, and enhance tumor penetration in HR⁺/HER2⁻ metastatic breast cancer, RCC (renal cell carcinoma), and NET (neuroendocrine tumors).
The presentation will occur at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9-12, 2025, in San Antonio, Texas.
Sapu003 was developed by Sapu Nano, which is a joint venture between Oncotelic Therapeutics and Dragon Oversea. Oncotelic is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products.
Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. The company also owns 45% of GMP Bio, another joint venture advancing complementary drug candidates.
Sapu003 is designed to improve bioavailability, reduce toxicity, and enhance tumor penetration, which could provide significant advantages over existing everolimus formulations for treating HR⁺/HER2⁻ metastatic breast cancer, RCC, and NET.
The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences sectors, providing press release distribution, article syndication, social media distribution, and corporate communications solutions as part of the IBN network.
Oncotelic focuses on addressing high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates, including HR⁺/HER2⁻ metastatic breast cancer, RCC, and NET through its Sapu003 program.
Curated from InvestorBrandNetwork (IBN)
